regal must have spent significant time and effort($) behind the scenes to do their own due diligence and obviously DFA lenders did probably even more DD - the real reason for OPT ph3 failure will come out in time - and it is not because eylea/lucentis has suddenly became 70% more effective after 15 years in the market. Bad trial design and bad execution is probably the most obvious reasons. sozinibercept clearly works as per phase 2b data which has been peer reviewed in many medical journals.
- Forums
- ASX - By Stock
- AFR: Phil King’s Regal writes Opthea to zero and backs off risky bets
OPT
opthea limited
Add to My Watchlist
0.00%
!
60.0¢

regal must have spent significant time and effort($) behind the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
OPT (ASX) Chart |
Day chart unavailable
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online